Skadden advised Innovent Biologics in its global strategic partnership with Takeda to bring certain of Innovent’s oncology drugs to the global market. Innovent will receive a $1.2 billion upfront payment. The Skadden team included Paloma Wang and Brian Egan.
by Rohin Pujari
